High Molecular Weight Forms of Deferoxamine: Novel Therapeutic Agents for Treatment of Iron-Mediated Tissue Injury

  • Bo E. Hedlund
  • Philip E. Hallaway
  • John R. Mahoney
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 264)


The iron chelator, deferoxamine (Desferal®), is presently used clinically for the treatment of acute and chronic iron toxicity. The chelator is an effective inhibitor of iron-catalyzed reactions leading to the formation of both oxygen and lipid-derived radicals. Deferoxamine (DFO) has been incorporated in a number of studies involving oxygen and lipid radical mediated reactions leading to tissue injury and has proven efficacious in ameliorating reperfusion injury.


Ferrous Sulfate Hydroxyethyl Starch Oral Iron High Molecular Weight Form Ferrous Gluconate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Mazur, S. Baez, and E. Shorr, The mechanism of iron release from ferritin as related to its biological properties, J. Biol. Chem. 213:147 (1955).PubMedGoogle Scholar
  2. 2.
    C. E. Thomas, L. A. Morehouse, and S. D. Aust, Ferritin and superoxide-dependent lipid peroxidation, J. Biol. Chem. 260:3275 (1985).PubMedGoogle Scholar
  3. 3.
    P. Biemond, A. J. G. Swaak, C. M. Biendorff, and J. F. Koster, Superoxide-dependent and independent mechanisms of iron mobilization from ferritin by xanthine oxidase, Biochem. J. 239:169 (1986).PubMedGoogle Scholar
  4. 4.
    M. S. Paller, and B. E. Hedlund, Role of iron in postischemic renal injury in the rat,KidneyInt. 34:474 (1980).CrossRefGoogle Scholar
  5. 5.
    G. Ambrosio, J. L. Zweier, W. E. Jacobus, M. L. Weisfeldt, and J. T. Flaherty, Improvement of postischemic myocardial function and metabolism induced by administration of defer oxamine at the time of reflow: The role of iron in the pathogenesis of reperfusion injury, Circulation 76:906 (1987).PubMedCrossRefGoogle Scholar
  6. 6.
    S. F. Badylak, A. Simmons, J. Turek, and C. F. Babbs, Protection from reperfusion injury in the isolated rat heart by postischemic deferoxamine and allopurinol administration, Cardiovasc. Res. 21:500 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    R. Bolli, B. S. Patel, W. X. Zhu, P. G. ONeill, M. L. Charlat, and R. Roberts, The iron chelator deferoxamine attenuates postischemic ventricular dysfunction, Am. J., Physiol. 253: H1372-H1380 (1987).Google Scholar
  8. 8.
    N. E. Farber, G. M. Vercellotti, H. S. Jacob, G. M. Pieper, and G. J. Gross, Evidence for a role of iron in functional and metabolic stunning in the canine heart, Circ. Res. 63:351 (1988).PubMedGoogle Scholar
  9. 9.
    B. R. Reddy, R. A. Kloner, and K. Przyklenk, Early treatment with deferoxamine limits myocardial ischemia/reperfusion injury, Free Rad. Biol. Med., in press (1989).Google Scholar
  10. 10.
    C. F. Babbs, The role of iron ions in the genesis of reperfusion injury following successful cardipulmonary resuscitation: Preliminary data and a biochemical hypothesis, Ann. Emerg. Med. 14:777 (1985).PubMedCrossRefGoogle Scholar
  11. 11.
    S. Sanan, G. Sharma, R. Malhotra, D. P. Sanan, P. Jain and P. Vadhera: Protection by desferrioxamine against histopathological changes of the liver in the post-oligaemic of clini cal haemomorrhagic shock in dogs: Correlation with improved survival rate and recovery. Free Rad. Res. Commun. 6:29 (1989).CrossRefGoogle Scholar
  12. 12.
    C. F. Whitten, G. W. Gibson, M. H. Good, J. F. Goodwin, and A. J. Brough, Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: Clinical observations, experimental studies, and theoretical considerations, Pediatrics 36:322 (1965).Google Scholar
  13. 13.
    C. F. Whitten, Y-C. Chen, and G. W. Gibson, Studies in acute iron poisoning: II. Further observations on desferrioxamine in the treatment of acute experimental iron poisoning, Pediatrics 38:102 (1966).PubMedGoogle Scholar
  14. 14.
    A. Slivka, J. Kang, and G. Cohen, Hydroxyl radicals and the toxicity of oral iron, Biochem. Pharmacol. 35:553 (1986).PubMedCrossRefGoogle Scholar
  15. 15.
    J. O. Kang, A. Slivka, and G. Cohen, In vivo formation of hydroxyl radicals following intragastric administration of ferrous salts in rats, J. Inorg. Biochem. 35:55 (1989).PubMedCrossRefGoogle Scholar
  16. 16.
    J. O. Hoppe, G. M. A. Marcelli, and M. L. Tainter, An experimental study of the toxicity of ferrous gluconate, Am. J. Med. Sri. 230:491 (1955).CrossRefGoogle Scholar
  17. 17.
    P. E. Hallaway, J. W. Eaton, S. S. Panter, and B. E. Hedlund, Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers, Submitted for publication (1989).Google Scholar
  18. 18.
    T.L. Litovitz, B.F. Schmitz, N. Matyunas and T.G. Martin. 1987 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am. J. Emer. Med. 6:479 (1988).CrossRefGoogle Scholar
  19. 19.
    C. E. Ganote, and G. Nahara, Acute ferrous sulfate hepatotoxicity in rats. An electron microscopic and biochemical study, Lab. Invest. 28:426 (1973).PubMedGoogle Scholar
  20. 20.
    E. Graf, J. R. Mahoney, Jr., J. R. Bryant, and J. W. Eaton, Iron-catalyzed hydroxyl radical formation: Stringent requirement for iron-coordinated water, J. Biol. Chem. 295:3620 (1984).Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Bo E. Hedlund
    • 1
  • Philip E. Hallaway
    • 1
  • John R. Mahoney
    • 2
  1. 1.Biomedical Frontiers, Inc.MinneapolisUSA
  2. 2.University of MinnesotaMinneapolisUSA

Personalised recommendations